Financial Data and Key Metrics Changes - Fourth quarter and full year core sales growth was in line with expectations, with a sequential improvement in the second half of 2024 compared to the first half [12] - The company reported a 3.4% core sales decline for the year, despite experiencing category contraction [13] - Normalized gross margin improved by 460 basis points to 34.1% for the full year compared to 2023, marking the highest full-year normalized gross margin since 2018 [14][47] - Normalized operating margin increased by 210 basis points to 8.2%, driven by improved gross margin [15] - The company generated nearly 500millionofoperatingcashflow,allowingforareductionindebtandaleverageratioof4.9timesatyear−end[16][51]BusinessLineDataandKeyMetricsChanges−Coresalestrendsimprovedacrossallsixbusinessunits,withthreeunitsturningpositivefortheyear,specificallyinbaby,writing,andcommercialbusinesses[12]−Thelearninganddevelopmentsegmentandtheinternationalbusinessachievedpositivecoresalesgrowthinallquartersof2024[12]−Fourthquartercoresalesweredown32 billion in US manufacturing since 2017, positioning itself competitively against peers [95] Q&A Session Summary Question: Focus on organic or core sales growth for 2025 - Management expects core sales guidance for 2025 to be between -2% and +1%, with a significant sequential improvement anticipated [73][74] Question: Clarity on Q1 core sales drivers - Q1 is typically the smallest quarter, and management does not read too much into it as an indicator for the year [100] Question: Practical tariff exposure in China - Current exposure is at 15%, expected to reduce to 10% by year-end, primarily related to the baby business [126]